Circulating tumor DNA (ctDNA) sensitivity remains subpar for molecular residual disease
(MRD) detection in bladder cancer patients. To remedy this problem, we focused on the …

Molecular stratification can improve the management of advanced cancers, but requires
relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a …

Purpose: Next-generation sequencing (NGS)-based profiling of both urinary tumor DNA
(utDNA) and circulating tumor DNA (ctDNA) shows promise for noninvasive detection and …

Background and objective Circulating tumor DNA (ctDNA) can be used for sensitive
detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in …

PURPOSE Novel sensitive methods for early detection of relapse and for monitoring
therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately …

Background Neoadjuvant chemotherapy (NAC) is the standard of care in muscle-invasive
bladder cancer (MIBC). However, treatment is intense, and the overall benefit is small …

Background The standard of care treatment for muscle-invasive bladder cancer (MIBC) is
radical cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the …

BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic
urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not …

Circulating tumor DNA (ctDNA) can be a prognostic biomarker for non-muscle-invasive
bladder cancer (NMIBC); however, targeted sequencing has not been performed to detect …

BACKGROUND Current noninvasive assays for urothelial carcinoma (UC) lack clinical
sensitivity and specificity. Given the utility of plasma cell-free DNA (cfDNA) biomarkers, the …